

## POSTER LISTING

Poster ID	First author	Title
<b>Molecular Pathways (MP19)</b>		
MP19_1	Abdelraouf, N.	Visualizing the effect of lymphatic pump techniques on T lymphocytes absolute count in normal subjects: Randomized control trial
MP19_2	Cook, L.	Molecular remissions are observed in chronic adult T-cell leukaemia/lymphoma in patients treated with mogamulizumab
MP19_3	Mehta-Shah, N	Romidepsin in combination with gemcitabine, oxaliplatin, and dexamethasone shows durable responses in aggressive lymphomas: Phase I results
MP19_4	Rodriguez, M.	Molecular signature in T-cell lymphoma
<b>Novel Therapies (NT19)</b>		
NT19_1	Bachy, E.	Whole-genome CRISPR/Cas9 screens uncover the C-terminal portion of the long-isoform of cFLIP as essential for PTCL survival
NT19_2	Kalac, M.	Constitutive phosphorylation of CYLD promotes ATLL survival by inhibiting RIPK1-dependent cell death
NT19_3	Negoro, E.	Combined antitumor effects of darinaparsin and other antitumor drugs in hematologic malignant cell lines
<b>NT19_4</b>	<b>Oiwa, K.</b>	<b>Characterization of newly established pralatrexate-resistant cell lines.</b>
NT19_5	Shustov, A.	Management of mucositis with the use of leucovorin as adjunct to pralatrexate in treatment of peripheral T-cell lymphomas.
<b>Cutaneous T-Cell Lymphoma (CTCL19)</b>		
CTCL19_1	Abbasi, A.	Tumor flare reaction in a patient with cutaneous T-cell lymphoma treated with brentuximab and lenalidomide associated with durable disease control
CTCL19_2	Ahlawat, S.	A multi-centre retrospective analysis of outcomes following allogeneic stem-cell transplant in patients with cutaneous T-cell lymphoma
CTCL19_3	Ai, W.	Phase I study of romidepsin and liposomal doxorubicin in relapsed or refractory T-cell lymphoma
CTCL19_4	Allen, P.	Sequence of treatment and prognosis in advanced cutaneous-T-cell lymphoma: The Emory Experience
CTCL19_5	Bagot, M.	Long-term clinical benefit with mogamulizumab in previously treated cutaneous T-cell lymphoma (CTCL): Results from the Phase 3 MAVORIC Study
CTCL19_6	Chen, L.	Mogamulizumab-induced cutaneous granulomatous drug eruption mimics mycosis fungoides but marks durable clinical response
CTCL19_7	Dong, N.	Coexistence of cutaneous T-cell lymphoma and Kaposi Sarcoma in immunodeficient hosts – a report of two cases
CTCL19_8	Foss, F.	Phase 1 Trial of cobomarsen, a miR-155 Inhibitor, in HTLV-1 associated adult T cell lymphoma/leukemia
<b>CTCL19_9</b>	<b>Goyal, A.</b>	<b>The epidemiology of primary cutaneous gamma/delta T-cell lymphoma: A SEER-18 analysis</b>
CTCL19_10	Goyal, A.	Increased risk of second primary hematologic and solid malignancies in patients with mycosis fungoides
CTCL19_11	Hudgens, S.	Evaluation of symptom and side effect bother in cutaneous T-cell lymphoma patients treated with Mogamulizumab or Vorinostat
CTCL19_12	Moerman-Herzog, A.	Comparison of gene expression of Sézary syndrome and lymphocytic variant hypereosinophilic syndrome reveals a subset of concordant genes
CTCL19_13	Querfeld, C.	Results from Phase 1 Trial of Cobomarsen, an Inhibitor of miR-155, in Mycosis Fungoides (MF)
CTCL19_14	Querfeld, C.	Phase 1/2 trial of Durvalumab (anti-PD-L1) +/- Lenalidomide in Patients with Cutaneous T cell Lymphoma Preliminary Results of Phase I and Correlative Studies.
CTCL19_15	Semenov, Y.	Stage-specific quality of life burden in patients with cutaneous T-cell lymphoma: comparison of generic and dermatology-specific instruments
CTCL19_16	William, B.	Brentuximab vedotin (BV) and lenalidomide (Len) in relapsed and refractory T-cell lymphomas: Interim results of a phase II trial
CTCL19_17	Zinzani, PL.	Mogamulizumab efficacy by prior systemic therapy in patients previously treated for cutaneous T-Cell lymphoma: A MAVORIC Study Post-Hoc analysis

Poster ID	First author	Title
<b>Transplant (TR19)</b>		
TR19_1	Herrera, D.	Barriers and Outcomes of Allogeneic Stem Cell Transplant (AlloSCT) for Adult T-Cell Lymphoma-Leukemia (ATLL) in the US in a major tertiary center
TR19_2	Mingzi, Y.	A retrospective study of the CHOP, CHOPE and CHOPE/G regimens as the first-line treatment of peripheral T-cell lymphomas
<b>TR19_3</b>	<b>O'Connor, O.</b>	<b><i>The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled, Global Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Previously-Untreated Subjects with CD30-expressing Peripheral T-Cell Lymphomas</i></b>
TR19_4	Yoon, JJ.	Survival after Allogeneic Stem Cell Transplantation in Peripheral T-Cell Lymphoma at Emory University Hospital
TR19_5	Yoon, JJ.	Survival after Autologous Stem Cell Transplantation in Peripheral T-Cell Lymphoma at Emory University Hospital
<b>Subtypes (ST19)</b>		
ST19_1	Jun Ho, Y.	A multicenter retrospective analysis of clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma
ST19_2	Lee, J.	Blastic plasmacytoid dendritic cell neoplasm in a 68-year-old FILIPINO male: A case report
<b>ST19_3</b>	<b>Mehta-Shah, N</b>	<b><i>Duvelisib and Romidepsin is highly active in peripheral T-cell lymphoma: Results of parallel multicenter, Phase 1 studies with expansion cohorts</i></b>
ST19_4	Yoo, KH.	Clinical outcome and prognostic factors in patients with T-cell and NK-cell lymphomas admitted to intensive care unit
ST19_5	Zain, J.	The PRIMOTM Study: A Phase 2 Study of Duvelisib Efficacy and Safety in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
<b>Registries (REG19)</b>		
REG19_1	Chiattonne, C.	The T-Cell Brazil Project: A pioneering study to create a registry of T-Cell Lymphomas covering all Brazilian regions
<b>REG19_2</b>	<b>Stuver, R.</b>	<b><i>Role of single agent and combination chemotherapy strategies in relapsed/refractory peripheral T-cell lymphoma: Results from the COMPLETE Registry</i></b>
<b>Industry Innovation (II19)</b>		
II19_1	Horwitz, S.	The Novel SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in a Phase 2 Study in Relapsed/Refractory PTCL and CTCL
II19_2	Janc, J.	Biochemical, Immunologic and In Vivo Preclinical Studies with CPI-818: A Selective Interleukin-2-Inducible T-cell Kinase Inhibitor That Inhibits T-Cell Receptor Signaling, Promotes Th1 Skewing, and is Efficacious in Dogs with T-Cell Lymphomas
II19_3	Porcu, P.	Viral Gene Activation Approach Shows Promise in Targeting EBV+ Angioimmunoblastic T-cell Lymphoma: Combination of Nanatinostat and Valganciclovir